Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
ConclusionsAdjuvant docetaxel without prednisone did not improve BDFS after radical RT with ADT for intermediate- or high-risk PCa.Patient summaryWe compared six cycles of adjuvant docetaxel given after radical external radiotherapy plus androgen deprivation therapy to surveillance in intermediate- and high-risk localised prostate cancer. We found no overall benefit in this setting.
ConclusionsProton beam radiotherapy for prostate cancer is feasible with a low rate of acute toxicity and promising late toxicity and effectivity.
Condition: Prostate Cancer Intervention: Drug: Pembrolizumab Sponsors: CHU de Quebec-Universite Laval; Merck Sharp & Dohme Corp. Not yet recruiting
Conclusions: We found a highly reliable FI network, which revealed LIFR, PIK3R1, and MMP12 as novel prognostic biomarker candidates for GBC. These findings could accelerate biomarker discovery and therapeutic development in this cancer. Introduction Gallbladder cancer (GBC), the sixth most common gastrointestinal cancer, is an uncommon but challenging disease. Its incidence has recently increased highly worldwide (1). The risk factors for GBC include sex, aging, obesity, chronic cholecystitis, and cholelithiasis (2, 3). Because of the lack of an effective early diagnostic method, the disease often is not diagnosed ...
Conclusion: Fat fraction on MRI corresponded to fat content on histology and therefore contributes to lesion characterization. Measurement repeatability was excellent for ADC; this parameter increased significantly post-radiotherapy even in disease categorized as stable by size criteria, and corresponded to cellularity on histology. ADC can be utilized for characterizing and assessing response in heterogeneous retroperitoneal sarcomas. Introduction Soft-tissue sarcomas are often highly heterogeneous tumors with variable components that can include cellular tumor, fat, necrosis, and cystic change. In many soft-tissue ...
CONCLUSION: Adding surgery in a multimodal treatment model in high-risk prostate cancer showed significantly better survival outcome compared with the current standard of radiotherapy. Surgery in this group is, therefore, compelling and that also includes a clinical T3-stage of the disease. The study is limited by possible selection bias for the two treatment models. PMID: 30990112 [PubMed - as supplied by publisher]
Purpose: Biochemical response to neoadjuvant androgen deprivation therapy (nADT) predicts recurrence-free and overall survival for prostate cancer (PCa). However, PSA levels often become undetectable following nADT and may not reflect the true extent of tumour cell kill. Our previous work on magnetic resonance imaging (MRI) of high-risk patients showed significant changes in textural radiomic features in response to nADT demonstrating their potential as surrogate biomarkers . We aimed to validate these changes and evaluate their reproducibility using test –retest MRI scans before and after nADT.
A 62-year-old man presented with nocturia and urinary frequency and was found to have an elevated prostate-specific antigen level of 14.2 μg/L. Diagnostic magnetic resonance imaging of the pelvis and prostate showed a T2c prostate tumor, and transrectal ultrasound-guided biopsy findings confirmed a group 4 prostate adenocarcinoma according to the Gleason grade. A radioisotope bone scan confirmed no evidence of bone metastases. The patient received neoadjuvant androgen deprivation therapy (ADT) followed by radical radiation therapy to the prostate to a dose of 60 Gy in 20 fractions. The pelvic nodes were not treated.
Tumor hypoxia is associated with radioresistance and poor prognosis after radiation therapy for prostate cancer (PCa). In this prospective pilot study, we assessed the ability of 18F-misonidazole (18F-MISO) positron emission tomography (PET) –magnetic resonance imaging (MRI) to detect hypoxia in high-grade PCa patients who were candidates for curative radiation therapy, and we evaluated 18F-MISO PET-MRI modulation after 3 months of neoadjuvant androgen deprivation therapy (nADT).
Conclusions Although EAU guidelines for PCa management are easily available in Europe, the adherence to their recommendations is low, finding the highest discrepancies in the need for a prostate biopsy and the diagnostic methods. Improve information and educational programs could allow a higher adherence to the guidelines and reduce the variability in daily practice (Controlled-trials.com: ISRCTN19893319).